# Next Session — Session 69

**Prepared:** 2026-05-27  
**Phase:** Phase 6 — Fact Connectivity & Canonical Display  
**Session 68 complete:** Failure cascade risk badge ✅ · makeTabGrids null guards ✅ · Subsidiary display ✅ · Deal count hint fix ✅ · Deployed commit `313a923a8759`

---

## Session 68 — What Was Built

### Bug Fixes (Critical)

| Fix | What | Result |
|---|---|---|
| `makeTabGrids` null guards | `grid-${prefix}-readouts/landscape` render calls in `makeTabGrids` had no null guard — crashed ALL tabs (TSLP fix from session 67 was only a partial fix) | ✅ No more Container null errors |
| `initGrids` TSLP guards | Line 10024 — already fixed in commit `498fe790d350` (session 67) | ✅ |

### UI Features Added

| Feature | Location | Details |
|---|---|---|
| Failure cascade risk badge | `openDrugEntityModal` + `_cemDrugBody` | Queries `failure_cascade_risk` view; shows HIGH/MEDIUM/LOW banner with mechanism + rationale. IMVT-1402 shows ⚠ HIGH RISK · FcRn × TED failed |
| Subsidiary + acquired entity display | `_cemCompanyBody` | Shows both `status='subsidiary'` (SUBSIDIARY pill) and `status='acquired'` (ACQUIRED pill) entities in company card header. AbbVie shows Ventyx Biosciences (ACQUIRED) |
| Deal count hint fix | `_cemDrugBody` | `'1 deal'` hardcoded → now shows actual count (`_allDeals.length + ' deals'`) |

### Deployment

| Commit | SHA | What |
|---|---|---|
| Session 67 TSLP fix | `498fe790d350` | initGrids TSLP null guards |
| Session 68 all features | `313a923a8759` | makeTabGrids null guards + cascade risk badge + subsidiary display + deal count |

### Key Test Results

| Test | Result |
|---|---|
| IMVT-1402 drug card cascade risk | ✅ `HIGH, FcRn × TED, failed, "Mechanism has failed in Phase 3..."` |
| `failure_cascade_risk` view health | ✅ 17 rows live |
| AbbVie subsidiaries query | ✅ Returns `[{id:'ventyx', name:'Ventyx Biosciences', status:'acquired'}]` |
| No Container null errors | ✅ Confirmed clean console after CDN propagated |

---

## Priority 0: Session Start Validation

```sql
-- 1. Check open governance violations
SELECT table_name, row_id, rule_name, description
FROM governance_violations WHERE resolved = FALSE;

-- 2. Check drug validation failures
SELECT drug_id, rule_name, result, details
FROM drug_validation_results WHERE result IN ('fail', 'warning')
ORDER BY result, drug_id LIMIT 20;

-- 3. Verify failure_cascade_risk still returning rows
SELECT drug_name, cascade_risk_level, mechanism_target, mechanism_indication
FROM failure_cascade_risk ORDER BY cascade_risk_level, drug_name;
```

---

## Priority 1: Apply geo_approval_gaps View (Manual — 5 min)

The `geo_approval_gaps` VIEW was defined in `migrations/v40_geographic_approvals_expansion.sql` but was never applied to the database. The Supabase SQL editor was inaccessible via automation in session 68.

**Apply manually via Supabase SQL Editor** (`https://supabase.com/dashboard/project/tghntyofptvfhmtchwcv/sql/new`):

```sql
CREATE OR REPLACE VIEW geo_approval_gaps AS
SELECT
  d.id,
  d.name,
  d.brand_name,
  d.stage,
  bool_or(ga.geography = 'US' AND ga.approval_type != 'pending') as approved_us,
  bool_or(ga.geography = 'EU' AND ga.approval_type != 'pending') as approved_eu,
  bool_or(ga.geography = 'Japan' AND ga.approval_type != 'pending') as approved_japan,
  bool_or(ga.geography = 'China' AND ga.approval_type != 'pending') as approved_china,
  bool_or(ga.geography = 'US' AND ga.approval_type = 'pending') as pending_us,
  COUNT(DISTINCT ga.geography) as geo_count,
  COUNT(DISTINCT ga.indication) as indication_count
FROM drugs d
LEFT JOIN geographic_approvals ga ON ga.drug_id = d.id
WHERE d.stage ILIKE '%approv%'
   OR d.brand_name IS NOT NULL
   OR ga.id IS NOT NULL
GROUP BY d.id, d.name, d.brand_name, d.stage
ORDER BY d.name;
```

Verify: `SELECT * FROM geo_approval_gaps LIMIT 5;`

---

## Priority 2: COMPETES_WITH Edge Backfill

From session 66 audit: ~714 of ~1,000 expected COMPETES_WITH edges exist. ~286 missing.

```sql
-- Find drugs sharing target × indication without a COMPETES_WITH edge
SELECT d1.id as drug1, d2.id as drug2
FROM drugs d1
JOIN drug_targets dt1 ON dt1.drug_id = d1.id
JOIN drug_targets dt2 ON dt2.target_id = dt1.target_id AND dt2.drug_id != d1.id
JOIN drugs d2 ON d2.id = dt2.drug_id
LEFT JOIN entity_edges ee ON ee.from_entity_id = d1.id 
  AND ee.to_entity_id = d2.id AND ee.edge_type = 'COMPETES_WITH'
WHERE ee.id IS NULL
LIMIT 20;
```

Approach: Script using drug_area_scores.overlap IN ('direct', 'adjacent') as the source.

---

## Priority 3: drug_sources Backfill

Table has 0 rows. Run enrichment on ~80 drugs with `data_confidence = 'unverified'`:

```sql
SELECT stage, COUNT(*) total, 
  COUNT(CASE WHEN data_confidence = 'unverified' THEN 1 END) unverified
FROM drugs GROUP BY stage ORDER BY total DESC;
```

---

## Priority 4: COMPETES_WITH Visualization in Drug Card

Now that failure cascade risk is wired, next logical step: surface competitive relationship edges (COMPETES_WITH) in the drug card. Query `entity_edges WHERE edge_type='COMPETES_WITH' AND (from_entity_id=drug.id OR to_entity_id=drug.id)` and render as a "Competing programs" cell.

---

## Priority 5: Ventyx Company Card Slow Render

The AbbVie company card takes >8 seconds to render because `openCompanySlideOver` fetches trials in a serial loop for each drug (line 10537). For companies with large pipelines (AbbVie has dozens of drugs), this compounds.

**Fix**: Batch the trial fetch with `.in('drug_id', drugIds)` instead of looping:
```javascript
// Replace serial loop with parallel batch
const { data: trialsData } = await _sb.from('trials')
  .select('*').in('drug_id', drugs.slice(0,8).map(d=>d.id));
trials = trialsData || [];
```

---

## Priority 6: Mechanism Status Coverage Expansion

Current: 33 rows in `mechanism_status`. The `failure_cascade_risk` view only surfaces risks for mechanisms WITH a failure/weakness record. Consider adding records for additional critical mechanisms:

- TL1A × IBD (phase_3, active — multiple Phase 3 programs running)
- IL-4Rα × AD (approved — dupilumab canonical)
- TSLP × Asthma (approved — tezepelumab)

These would allow the cascade risk view to also surface LOW risk / validated precedents.

---

## Session 68 End State — Connectivity Depth Chain

| Table | Stored | Linked | Status |
|---|---|---|---|
| `catalysts` | 794 | 534 drug_id | ✅ |
| `news_articles` | 55 | 55 | ✅ |
| `intel` | 776 | 637 indication, 1288 target | ✅ |
| `mechanism_status` | 33 | 33 indication_id+target_id | ✅ |
| `failure_cascade_risk` | 17 | live VIEW | ✅ **wired to UI Session 68** |
| `deals` | 204 | linked to drug card | ✅ **count fixed Session 68** |
| `drug_sources` | 0 | — | ⚠️ EMPTY |
| `geo_approval_gaps` | — | VIEW missing | ⚠️ NEEDS MANUAL APPLY |

---

## What NOT to Do in Session 69

- Do not touch `drug_areas` biological reads (Phase 5 freeze)
- Do not merge Roche/Genentech, Prometheus/Merck, or Ventyx/AbbVie into single entities
- Do not run new AI enrichment / signal generation
- Do not modify `_resolveStage` logic
- Do not add new indication ontology entries without checking `indication_ontology_governance.md`

---

## Modified Files — Session 68

| File | Change |
|---|---|
| `index.html` | makeTabGrids null guards (lines 10052, 10065) |
| `index.html` | `_cemDrugBody` + `cascadeRisk` param + banner HTML |
| `index.html` | `openDrugEntityModal` cascade risk query |
| `index.html` | `_cemCompanyBody` subsidiary banner expanded (acquired + active) |
| `index.html` | Deal count hint fixed (`_allDeals.length` instead of `'1 deal'`) |
| `NEXT_SESSION.md` | This file |

**Supabase — no changes this session** (geo_approval_gaps VIEW pending manual apply)
